|Bid||0.9300 x 800|
|Ask||0.9800 x 1100|
|Day's Range||0.9330 - 0.9979|
|52 Week Range||0.6200 - 5.6700|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.